Leelavathy Budamakuntla, Eswari Loganathan, Pavithra Gundappa, Sreelakshmi and Tapasya Kini and Kavya K
Background: Psoriasis, a disease of abnormal epidermal proliferation, was found to be T helper-1 disease. Currently a new concept of T Helper 17 has been found to play a major role through
IL-17 and IL-22 cytokines in the disease pathogenesis.
Aim: Since IL 17 is one of the key effector cytokine of Th17 pathway, we conducted a 12 week longitudinal study of effect of NBUVB phototherapy and Methotrexate on serum IL 17 levels in patients with psoriasis before and after treatment.
Materials and Methods: This was a prospective longitudinal study done on 28 psoriasis patients with PASI>10 and 10 controls. Serum IL-17 levels and PASI scoring was estimated at baseline and after 12 weeks after therapy with weekly intramuscular injection of 15mg of methotrexate and biweekly NBUVB phototherapy.
Results: Baseline PASI score was 24.23 ± 7.5 which reduced to 9.66 ± 4.2 (P value<0.0001). The serum IL 17 level at baseline was 2.65 ± 0.7 pg/ml. which reduced to 1.99 ± 0.57 pg/ml, P value<0.0001. Serum Interleukin 17 level of the psoriasis patients at baseline was 2.65 ± 0.7 pg/ml compared to 2.5 ± 0.9pg/ml in the controls. The difference is not statistically significant. There was a positive correlation between the serum levels of IL-17 and severity
of PASI score (
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi